Originally published at americanbanker.com on March 15, 2024. In a bold move that may reshape the U.S. consumer finance landscape, Rohit Chopra’s Consumer Financial Protection Bureau has issued Consumer Financial Protection Circular 2024-01, marking a significant overreach into how Americans access financial services. This circular scrutinizes digital intermediaries, such as comparison-shopping tools and lead generators, dictating […]
The Southwest Public Policy Institute (SPPI), a leading advocate for policy solutions that enhance freedom and prosperity in the Southwest, today announced its support for the Competitive Enterprise Institute-led coalition opposing the RECOUP Act (S. 2190). By signing the coalition letter, SPPI aligns itself with other prominent policy groups and experts in urging Congress to […]
Rethinking American Retirement and Social Security
Wells Fargo’s Flex Loan program is a labyrinth of unclear eligibility requirements and a baffling case of vanishing funds.
Experience shows that businesses pass on increased costs to consumers, hurting the very people wage hikes are supposed to help.
Rio Rancho, NM – The Southwest Public Policy Institute (SPPI) strongly condemns the Consumer Financial Protection Bureau (CFPB) for alleged racial discrimination against at least 85 Black and Hispanic employees. This follows news that the U.S. District Court for the District of Columbia has approved a $6 million settlement of class claims of alleged discrimination […]
If CFPB found a financial institution had suffered a data breach of a similar magnitude, the fines and fees would be astronomical.
The 2022 passage of House Bill 132, which set a stringent cap of 36% on interest rates for consumer loans, is having its intended and significant repercussions on New Mexico’s financial landscape. This was no accident: by restricting the interest rates that small-dollar lenders can charge, the rate cap effectively marginalized an entire segment of […]
Recent research has shown that health care consolidations not only lower costs for health care consumers but also improve multiple indicators of quality patient care.
Components of the Inflation Reduction Act have the very real potential of inflating drug prices with arbitrary price controls. Consumers will pay the price.
